Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of HRTIS.HE is 1.6 and suggests 33% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to
Buy
Sell